Acceleron Pharma (XLRN) Misses Q2 EPS by 14c

Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.77), $0.14 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.69 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c